– Data show rapid and durable engraftment with MGTA-456, an expanded cord blood stem cell product, in all 18 patients with hematologic malignancies across all conditioning regimens tested –
– MGTA-456 achieves clinical benefits of cord blood transplant –
– Clinically validated process to expand the numbers of CD34+ cells by >300 fold in single cord blood units significantly increases probability of identifying better HLA-matched stem cell donors for patients
December 11, 2017, CAMBRIDGE, Mass.–Magenta Therapeutics, a biotechnology company developing therapeutics to improve and extend the use of curative bone marrow transplant for more patients, today reported Phase 2 clinical data from its MGTA-456 hematopoietic stem cell (HSC) expansion program at the 59th annual meeting of the American Society of Hematology (ASH) in Atlanta, Ga. MGTA-456 is a single umbilical cord blood unit expanded with an aryl hydrocarbon receptor (AHR) antagonist. It is currently being studied in adult and pediatric patients with hematologic malignancies.